The consumer health product joint venture Pfizer Inc. has agreed to form with GlaxoSmithKline PLC could drive each firm toward its goal in the sector, even with GSK holding the upper hand as majority owner with initial control of potentially spinning off the JV.
The agreement announced Dec. 19 by the big pharmas could put consumer health where Pfizer wants it, entirely in the firm's rear-view mirror, and point both firms toward what they wants, more research and development funding freed up for the pharmaceutical ingredient operations that are their chief revenue drivers